SynAct Pharma to Participate in Investor and Partnering Conferences
(PR-inside.com) LUND, SE / ACCESS Newswire / September 22, 2026 / SynAct Pharma AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced its attendance and presentations at multiple upcoming…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


